Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Leveraging Telemedicine to Improve Guideline-Directed Medical Therapy Use and Outcomes Among Rural Patients With Heart Failure (RURAL-HF)

12 novembre 2026 aggiornato da: Ambarish Pandey, University of Michigan

Leveraging Telemedicine to Improve Guideline-Directed Medical Therapy Use and Outcomes Among Rural Patients With Heart Failure - the RURAL-HF Trial

The goal of this clinical trial is to learn if a new way of adjusting heart failure medicines can improve health in adults with heart failure who live in rural areas. This study tests whether remotely helping local doctors safely raise these doses faster can improve health over the first 3 months after leaving the hospital.

The main questions it aims to answer are:

  • Does the new approach help participants live longer, avoid needing a heart transplant or heart pump, stay out of the hospital for heart failure, and feel better day to day, over 6 months?
  • Do more participants take all their recommended heart failure medicines, at the best doses, by 6 months?
  • Does the new approach improve quality of life and daily activity, and how well does it work in everyday rural health care?

Participants will be placed by chance, like flipping a coin, into 1 of 2 groups: home monitoring alone or home monitoring plus medication optimization support. In the home monitoring alone group, participants' own doctors will manage their medicines as usual. In the medicine support group, heart failure specialists on the study team will use home readings and results from NT-proBNP blood tests, to send medicine advice to participants' own doctors. Researchers will compare the 2 groups to see if medicine support improves health and quality of life.

Participants will:

  • Use a scale, blood pressure cuff, and activity tracker at home for 3 months
  • May have routine blood tests ordered by their own doctor about 2 and 6 weeks after joining, if they are in the medicine support group
  • Complete video or phone study visits when they join, at 3 months, and at 6 months
  • Answer questions about their heart failure symptoms and quality of life at each visit
  • Some participants may also be asked to take part in an interview about their experience.

Panoramica dello studio

Descrizione dettagliata

Background and Rationale:

Rural communities experience persistent and widening disparities in cardiovascular outcomes, driven by adverse social determinants of health, limited access to specialty care, and structural barriers to timely treatment. Heart failure (HF) exemplifies these inequities, with rural patients experiencing higher mortality and poorer access to acute and longitudinal care despite a growing and aging HF population. Although guideline-directed medical therapy (GDMT) substantially improves outcomes in both heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF), real-world uptake and dose optimization remain low, particularly in rural settings, largely due to limited access to cardiac care, fragmented follow-up, and implementation challenges rather than true contraindications.

Telemedicine and remote patient monitoring (RPM) offer a practical strategy to address these barriers by expanding access to specialty input, enabling close physiologic monitoring, and supporting safe titration of GDMT medications without the need for frequent in-person visits. While early studies suggest that telehealth-enabled GDMT optimization can improve therapy uptake and outcomes, these approaches have not been rigorously evaluated in rural populations. This study addresses a critical evidence gap by testing a telemedicine-enabled, remote monitoring-supported strategy tailored to rural healthcare delivery, with the goal of improving GDMT optimization and reducing rural-urban disparities in HF care.

Study Design:

RURAL-HF is a randomized, open-label, Type 1 hybrid effectiveness-implementation trial comparing RPM alone vs. RPM combined with NT-proBNP-guided, provider-to-provider GDMT up-titration in patients recently hospitalized for HF in rural communities. Both arms receive remote monitoring devices for the first 90 days, isolating the effect of the NT-proBNP-guided GDMT titration intervention itself. The simultaneous collection of GDMT prescription, clinical, and implementation outcomes will inform future use and scalability should the intervention prove effective.

Participants will be enrolled at discharge from the index HF hospitalization or within 2 weeks of discharge. Participants will be randomly assigned 1:1 using a computerized algorithm. Block randomization will be performed by trial site and stratified by HF subtype (HFrEF/HFmrEF vs HFpEF) using REDCap. All recruitment and informed consent procedures will be conducted virtually using secure, HIPAA-compliant telehealth platforms. Blinding is not feasible because up-titration recommendations must be provided on the basis of physiologic data from remote monitoring.

Remote Patient Monitoring (Both Arms):

All participants, regardless of study arm, receive a cellular-connected device kit at enrollment. The kit includes a cellular-connected weight scale, a cellular-connected blood pressure and heart rate monitor, and a wrist-based watch that measures physical activity (step count). Devices arrive pre-configured and connect automatically to existing 4G/5G cellular networks, with no setup or home internet access required. This cellular-based approach enhances generalizability to rural populations by leveraging existing cellular tower infrastructure rather than requiring home broadband.

Participants are prompted to submit weight, heart rate, and blood pressure twice weekly for the first 6 weeks, decreasing to once weekly if no alert occurs, and returning to twice weekly if a new alert occurs. Remote monitoring alerts are reviewed, actioned, and closed by the study team. Active remote monitoring occurs from enrollment through 90 days for both arms.

RPM + NT-proBNP + GDMT Up-titration Arm:

The study team will provide GDMT initiation and titration recommendations to the participant's outpatient care team (primary care provider or cardiologist) on the basis of review of remote monitoring data. Recommendations will be delivered through asynchronous communication via the electronic health record, and the study team will offer at least one synchronous consultation (video or telephone) during the initial 90-day titration period. During the first 90 days post-discharge, the study team will review biometric data at least weekly and provide specific, evidence-based recommendations at one-to-two-week intervals until optimal or maximally tolerated GDMT is achieved. Recommendations will include specific medication suggestions (drug, dose, titration schedule) and laboratory-based monitoring instructions.

The study will employ a structured protocol integrating NT-proBNP levels, potassium, eGFR, and physiological safety parameters to guide GDMT optimization. Laboratory monitoring, including NT-proBNP and basic metabolic panels, will occur at weeks 2 and 6 as part of routine clinical care. NT-proBNP levels that remain stable or decline compared with pre-discharge baseline indicate safe conditions for beta-blocker up-titration, while NT-proBNP increases of more than 10% above pre-discharge levels will suggest withholding beta-blocker up-titration and instead increasing diuretic therapy to address potential worsening congestion. The participant's outpatient care team will implement recommendations through clinical encounters conducted according to their standard practice patterns. This approach is informed by STRONG-HF, which was associated with significantly greater uptake of GDMT and reduced risk of HF hospitalization or death at 180 days.

RPM Alone Arm:

Participants in the RPM alone arm receive the same device kit and remote monitoring for 90 days but do not have NT-proBNP testing or study-team GDMT titration recommendations. Remote monitoring alerts for this arm will be sent to the provider without recommendations for GDMT up-titration. Providers will receive general education surrounding GDMT use for patients with HF, and GDMT management is otherwise delivered according to standard community practice patterns.

Follow-up:

There will be three virtual study visits during the 6-month study period: a screening and baseline visit at enrollment, a 3-month follow-up visit coinciding with the end of the active 90-day RPM/GDMT titration period, and an end-of-study visit at 6 months. Between 90 days and 6 months, participants in both study arms will receive standard care from their outpatient providers without active study team intervention.

Statistical Analysis:

The primary endpoint will be analyzed using a stratified (by HF subtype), hierarchical win ratio approach, in which every participant in the RPM + NT-proBNP + GDMT arm is compared with every participant in the RPM alone arm over a shared follow-up time. The primary endpoint components and their hierarchy were determined after a survey of patients with HF, who noted that preventing mortality was the most important treatment outcome, followed by improving quality of life and avoiding hospitalization. A total of 598 participants will provide 80% power to detect a weighted stratified win ratio of 1.34 using a one-sided stratified win ratio Z-test with a Type I error rate of 0.025. The intent-to-treat population will include all randomized participants, analyzed according to their assigned treatment group. Pre-specified subgroup analyses of the primary endpoint will be conducted by sex, type of HF (HFrEF/HFmrEF vs. HFpEF), and racial/ethnic group.

Implementation Evaluation:

Implementation will be evaluated using the RE-AIM framework (reach, effectiveness, adoption, implementation fidelity, and maintenance), guided by the Implementation Research Logic Model and the Consolidated Framework for Implementation Research. An explanatory sequential mixed-methods design will combine quantitative implementation metrics with semi-structured key informant interviews with patients and caregivers (n=36, equally across study arms) and providers (n=12). Interviews will be audio or video recorded, transcribed verbatim, de-identified, and analyzed using rapid thematic analysis in Dedoose.

Tipo di studio

Interventistico

Iscrizione (Stimato)

600

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Michigan
      • Ann Arbor, Michigan, Stati Uniti, 48109
        • University of Michigan
        • Investigatore principale:
          • Ambarish Pandey, MD
        • Contatto:
    • Texas
      • Plano, Texas, Stati Uniti, 75093
        • Baylor Scott & White Cardiac Consultants - Plano
        • Contatto:
        • Investigatore principale:
          • Neil Keshvani, MD

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Age > 18 years old
  • Hospitalization for heart failure (HF) with intravenous diuretic use, with randomization within 14 days of discharge
  • Residing in a rural area (home address in a rural area as defined by the Federal Office of Rural Health Policy)
  • Established outpatient care (cardiology or primary care physician) at the participating sites
  • Eligible to receive at least 2 of 4 guideline-directed medical therapy (GDMT) classes for HF with reduced or mildly reduced ejection fraction (HFrEF or HFmrEF; beta-blocker, ACE inhibitor/ARB/ARNi, MRA, SGLT2 inhibitor), or at least 1 of 3 GDMT classes for HF with preserved ejection fraction (HFpEF; ACE inhibitor/ARB/ARNi, MRA, SGLT2 inhibitor), and not on target doses of these medication classes
  • Able to communicate with the study team via telephone or videoconference for study-related assessments and follow-up

Exclusion Criteria:

  • Stage D HF under consideration for or a recipient of advanced HF therapies, including left ventricular assist device (LVAD), heart transplant, or inotrope therapy
  • Discharge disposition to a nursing home, inpatient rehabilitation facility, or long-term care facility
  • Potassium > 5.5 mmol/L
  • End-stage kidney disease or eGFR < 25 mL/min/1.73 m²
  • Inability to provide informed consent
  • Pregnancy

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Remote patient monitoring + NT-proBNP & provider-to-provider support

Participants receive a cellular-connected device kit (weight scale, blood pressure and heart rate monitor, and wrist-worn activity tracker) with remote monitoring for 90 days following enrollment. In addition, the study team recommends NT-proBNP and basic metabolic panel testing at weeks 2 and 6, which the participant's outpatient care team may obtain as part of routine clinical care. The study team reviews biometric and laboratory data at least weekly and delivers specific, evidence-based GDMT initiation and titration recommendations (drug, dose, titration schedule, and laboratory monitoring instructions) to the participant's outpatient care team through asynchronous electronic health record communication at one-to-two-week intervals throughout the 90-day titration period. At least one synchronous video or telephone consultation is offered, with additional consultations available at the provider's preference. The participant's outpatient care team implements all medication changes.

The study team reviews remote monitoring data at least weekly, along with NT-proBNP and basic metabolic panel results from testing recommended at weeks 2 and 6 and obtained as part of routine clinical care. Recommendations for GDMT initiation and up-titration to optimal or maximally tolerated doses (drug, dose, titration schedule, and laboratory monitoring) are sent to the outpatient care team through the electronic health record every 1 to 2 weeks for 90 days, with at least one video or telephone consultation offered. A structured protocol integrating NT-proBNP, potassium, eGFR, blood pressure, and heart rate guides titration.

Participants receive a cellular-connected weight scale, blood pressure and heart rate monitor, and wrist-worn activity tracker that arrive pre-configured and require no home internet. Participants submit weight, heart rate, and blood pressure twice weekly for 6 weeks, then once weekly if no alerts occur. Step count is captured continuously. The study team reviews and actions alerts and contacts participants if no data are received for 7 days. Active monitoring continues for 90 days.

Comparatore attivo: Remote patient monitoring (RPM) alone

Participants receive the same cellular-connected device kit with remote monitoring for 90 days following enrollment. The study team may send safety alerts from remote monitoring to the participant's outpatient provider, without recommendations for GDMT up-titration. No recommendations for NT-proBNP testing and GDMT titration recommendations will be sent out by the study team. GDMT management, outpatient follow-up, and laboratory monitoring are delivered according to standard community practice by the participant's primary care provider or cardiologist.

Participants receive a cellular-connected weight scale, blood pressure and heart rate monitor, and wrist-worn activity tracker that arrive pre-configured and require no home internet. Participants submit weight, heart rate, and blood pressure twice weekly for 6 weeks, then once weekly if no alerts occur. Step count is captured continuously. The study team reviews and actions alerts and contacts participants if no data are received for 7 days. Active monitoring continues for 90 days.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Hierarchical Composite of All-Cause Mortality, Heart Transplantation or Ventricular-Assist Device, Heart Failure Hospitalizations, and Improvement in Kansas City Cardiomyopathy Questionnaire Score
Lasso di tempo: Baseline to 180 days

The primary endpoint is a hierarchical composite of all-cause mortality, heart transplantation or ventricular-assist device, HF hospitalization (yes/no), total number of HF hospitalizations, or a >5-point improvement in the Kansas City Cardiomyopathy Questionnaire (KCCQ). The endpoint will be assessed at 6 months using a stratified, hierarchical win ratio approach.

Baseline to 180 days

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Proportion of participants achieving optimal or maximally tolerated GDMT
Lasso di tempo: Baseline to 90 days

The proportion of participants achieving optimal or maximally tolerated GDMT will be evaluated as a secondary outcome. For participants with HFrEF or HFmrEF, target GDMT consists of optimal or maximally tolerated doses of an evidence-based beta-blocker and an ARNi (or ACE inhibitor/ARB if ARNi is not tolerated), an MRA at target dose, and an SGLT2 inhibitor. For participants with HFpEF, target GDMT consists of an optimal or maximally tolerated dose of an ARNi or ARB (preferred over ACE inhibitor) and any dose of an SGLT2 inhibitor and an MRA (finerenone or spironolactone). GDMT prescription will be assessed via electronic medical record and pharmacy review.

Baseline to 90 days
Heart Failure Collaboratory GDMT composite score
Lasso di tempo: Baseline to 180 days

GDMT utilization across all medication classes will also be assessed using the well-validated and prognostically meaningful composite HF Collaboratory score. The Heart Failure Collaboratory (HFC) GDMT score is a validated composite that measures overall guideline-directed medical therapy use. Points are assigned for prescription of each drug class (beta-blocker, ACEi/ARB/ARNi, MRA, and SGLT2i) and weighted by percentage of target dose. Higher scores reflect more complete therapy optimization.

Baseline to 180 days
Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score
Lasso di tempo: Baseline to 180 days

Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score. The KCCQ is a well-validated, HF-specific, patient-reported outcome measure and an FDA-endorsed measure of symptom and functional benefit. Scores range from 0 to 100, with higher scores indicating better health status.

Baseline to 180 days
Change in mean daily step count
Lasso di tempo: Baseline to 90 days, and baseline to 180 days

Change in mean daily step count, captured continuously via the wrist-worn activity device with remote monitoring. Step count provides an objective, continuously captured functional outcome that complements patient-reported quality of life and is less susceptible to reporting bias in this open-label design.

Baseline to 90 days, and baseline to 180 days
Implementation outcomes assessed using the RE-AIM framework
Lasso di tempo: Through study completion, up to 60 months

Implementation will be evaluated using the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework, with implementation assessed as fidelity. To understand contextual factors influencing implementation success, an explanatory sequential mixed-methods approach will combine quantitative implementation metrics with qualitative interviews of clinicians (n=12) and patients (n=36, stratified by study arm) to explore barriers, facilitators, acceptability, and differential effectiveness across patient subgroups, including age, sex, race/ethnicity, and socioeconomic position. Real-world implementation assessment is essential for translation beyond the trial setting.

Through study completion, up to 60 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Ambarish Pandey, MD, University of Michigan

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 dicembre 2026

Completamento primario (Stimato)

1 dicembre 2031

Completamento dello studio (Stimato)

1 dicembre 2031

Date di iscrizione allo studio

Primo inviato

12 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

12 novembre 2026

Primo Inserito (Effettivo)

18 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

18 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

12 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

Please contact the study team.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi